-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s EBI-031
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EBI-031 in Uveitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EBI-031 in Uveitis Drug Details:RG-6179 (EBI-031) is under development for the treatment of diabetic macular edema...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EBI-031 in Diabetic Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EBI-031 in Diabetic Macular Edema Drug Details:RG-6179 (EBI-031) is under development for the treatment of diabetic...
-
Product Insights
EBY Paraguay/ Yacyreta – Ana Cua Hydroelectric Power Plant 272 MW – Misiones
Equip yourself with the essential tools needed to make informed and profitable decisions with our EBY Paraguay/ Yacyreta - Ana Cua Hydroelectric Power Plant 272 MW - Misiones report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Net Present Value Model: Compass Pathways Plc’s Psilocybin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Prostate Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Prostate Cancer Drug Details: Isunakinra (EBI-005) was under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Colorectal Cancer Drug Details: Isunakinra (EBI-005) was under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Pancreatic Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Pancreatic Cancer Drug Details: Isunakinra (EBI-005) was under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Anal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Anal Cancer Drug Details: Isunakinra (EBI-005) was under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Bile Duct Cancer (Cholangiocarcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Isunakinra (EBI-005) was under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Triple-Negative Breast Cancer (TNBC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Triple-Negative Breast Cancer (TNBC) Drug Details: Isunakinra (EBI-005) was under development for...
-
Company Profile
![]()
Anadolu Efes Biracilik ve Malt San AS – Company Profile
Anadolu Efes Biracilik ve Malt San AS (Anadolu Efes) produces and sells beer, malt, and non-alcoholic beverages. The company also offers fruit juices, iced teas, water, energy and sports drinks, and teas. It markets and sells products under various brands including Erdinger, Efes Malt, Amsterdam Navigator, Marmara Gold, Kozel, Beck's And Duvel, for a few. The company operates its international business through its wholly-owned subsidiary Efes Breweries International NV (EBI) and also owns a majority stake in Coca-Cola Icecek A.S....
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Capivasertib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Capivasertib in Solid Tumor Drug Details: Capivasertib (AZD-5363) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Pancreatic Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Belzutifan in Pancreatic Tumor Drug Details:Belzutifan (Welireg), is an inhibitor of hypoxia-inducible factor-2a (HIF-2a). It is...
-
Company Profile
![]()
Enterprise Bancorp Inc – Company Profile
Enterprise Bancorp Inc (EBI) is a financial holding company that provides a wide range of personal and business banking, non-profit programs and services, and wealth management solutions. Its portfolio of offerings comprises deposit accounts such as checking and savings, card products such as debit and credit cards, and secured and unsecured loans for personal needs, vehicles, mortgages, small businesses, commercial real estate, construction, and line of credit. The company offers cash management solutions including deposits, payment, international services, fraud prevention,...
Add to Basket -
Company Profile
![]()
Ebix Inc – Company Profile
Ebix Inc (EBI) is a technology company. EBI offers e-commerce solutions and on-demand software related products. It also provides end-to-end solutions of infrastructure exchanges, agency systems, carrier systems and risk compliance solutions. EBI's services include software development, consultancy services, life insurance, risk management, health and employee benefits, CRM, applications software property and casualty insurance. It serves to insurance, financial, healthcare, manufacturing, technology and pharmaceutical industries. The company has presence in Brazil, Indonesia, Singapore, Australia, the US, UK, New Zealand, India...
Add to Basket -
Product Insights
![]()
Net Present Value Model: EBI-031
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EBI-031 Drug Details RG-6179 (EBI-031) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – EBI-01
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EBI-01 Drug Details EBI-01 is under development for the treatment of atopic dermatitis and...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – EBI-031
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EBI-031 Drug Details RG-6179 (EBI-031) is under development for the treatment of diabetic macular...
-
Product Insights
Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Liver Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery. The Liver Cirrhosis - Drugs in Development research report provides a comprehensive overview on the therapeutics under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.